Cardiovascular disease

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin for the treatment of symptomatic chronic heart failure (HF).  The drug is approved in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).  HF […]

New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function. The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with placebo. The results were presented […]

Individuals with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease, a large epidemiological study has revealed.  The research – led by KU Leuven in collaboration with colleagues in the UK, including the University of Glasgow, and published in The Lancet – shows for the first time that cardiovascular risks affect autoimmune […]

Research has shown which statins people with diabetes should be taking if they want to lower their “bad” cholesterol and prevent cardiovascular disease.  An analysis of data from 42 clinical trials showed the effectiveness of seven statins in lowering all types of bad cholesterol for patients with diabetes.   Bad cholesterol in the blood, known as non-high-density […]

Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England.  The collaboration received positive final recommendation from the National Institute for Health and Care Excellence (NICE) for use of inclisiran in primary care for the treatment of adult patients within its licenced indication1 who also have persistently elevated LDL-C […]

Silence Therapeutics and Nasdaq have announced positive topline data from the GEMINI Phase I study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anaemia conditions, thalassemia and myelodysplastic syndrome (MDS). The GEMINI Phase I, randomised, double-blind, placebo-controlled, single-ascending dose […]